Contract Research Organization (CRO) Services Market

The global Contract Research Organization (CRO) services market is expected to reach USD 125.95  billion in 2030 from USD 84.61 billion in 2025, at a CAGR of 8.3% during the forecast period. The factors driving the market growth include the increasing complexity and volume of trials; the growing focus on patient-centric clinical trials, such as Decentralized Clinical trials (DCTs); and the flexibility of services offered by CROs. Moreover, the upcoming therapeutic drugs patent cliff is fueling pharmaceutical companies to invest heavily in R&D activities and outsource their clinical trials to CROs. Additionally, the growing regulatory focus on patient diversity and data analysis offerings favoring customer reimbursement & marketing access strategies are some key opportunities for market players. However, challenges associated with the cybersecurity of patient data and sponsors’ intellectual properties and patient retention during trials hinder the market's growth to a certain extent.

The global CRO services market is competitive, with leading players contributing to a significant share, including IQVIA Inc. (US), ICON Plc. (Ireland), Thermo Fisher Scientific Inc. (US), Laboratory Corporation of America Holdings (LabCorp) (US), WuXi AppTec Co., Ltd. (China), Charles River Laboratories International, Inc. (US), Pharmaron Beijing Co., Ltd. (China), Medpace, Inc. (US), and Eurofins Scientific (Luxembourg), among others. The market players have undertaken acquisitions, agreements, collaborations, and geographic expansions to strengthen their positions in the global CRO services market.

To know about the assumptions considered for the study download the pdf brochure

IQVIA Inc. (US)

IQVIA Inc. is a global leader in clinical research services, distinguished by its blend of large-scale healthcare data, advanced analytics, and technology-enabled trial delivery. The company’s strategic focus is accelerating Phase I to IV execution through site & patient network orchestration, decentralized & hybrid trial models, and AI-driven feasibility, recruitment, and monitoring. Its portfolio spans clinical operations, medical writing, pharmacovigilance, and post-approval studies, integrated with real-world evidence and regulatory strategy support. IQVIA continues to invest in digital patient engagement, remote assessments, and risk-based quality management to streamline timelines and improve data integrity. For instance, in June 2025, IQVIA launched custom-built AI agents using NVIDIA technology designed to enhance workflows and accelerate insights for life sciences.

ICON plc (Ireland)

ICON plc is another key player in the CRO services market, strategically emphasizing end-to-end clinical development and flexible functional service partnerships for pharma, biotech, and medtech clients. The company differentiates through operational excellence, program governance, and digital tools that enhance patient recruitment, eConsent, and remote data capture. ICON’s therapeutic strengths include oncology, rare diseases, cell and gene therapy, vaccines, and infectious diseases, supported by specialized biomarker and late-phase capabilities. The acquisition of PRA Health Sciences (US) has added scale, diversified expertise, and deeper relationships with large sponsors while preserving agility for emerging biotechs.

Thermo Fisher Scientific Inc. (US)

Thermo Fisher Scientific delivers comprehensive CRO services across early and late-phase development, emphasizing operational speed, quality, and patient-centric design through its subsidiary, PPD, Inc. Strategically, PPD leverages Thermo Fisher’s broader ecosystem, including central labs, bioanalytical testing, and enabling technologies, to integrate laboratory science with clinical execution for more seamless, data-rich trials. Its capabilities span clinical operations, medical writing, pharmacovigilance, peri- and post-approval research, with growing use of decentralized assessments and digital patient engagement to reduce burden and improve retention.

Market Ranking

The CRO services market is competitive. The top five players for each market hold >35%, and the top ten account for a share of ~45-50%.

IQVIA maintains a strong position in the CRO services market through a comprehensive portfolio of services and enhancements using AI-based offerings. The company differentiates itself with its risk-based monitoring offerings. ICON plc has carved out a significant presence in the CRO services market with its diverse portfolio of services, offering flexible delivery models. Thermo Fisher Scientific Inc. (through PPD, Inc.) holds a strong position in the CRO Services market, driven by its offerings such as central lab and clinical operations-related services.

Related Reports:

Contract Research Organization (CRO) Services Market by Type (Early Phase, Clinical, Lab, Consulting), Therapeutic Area (Cancer (Breast, Lung), Infectious, Neurology, Vaccines), Modality (Small Molecules, Biologics, Biosimilars) - Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com